Time Horizon

12-18 months. Primary value event (LCA5 pivotal topline) is H2 2027. Near-term catalysts (shareholder vote Apr 20, BEST1 Cohort 1 mid-2026, RYZUMVI PDUFA Oct 2026) create intermediate inflection points, but the stock re-rates on gene therapy pipeline validation, not any single binary. DEMAND-type alpha with 365-day half-life. Not a catalyst trade.

Base Rate

Reference class: Pre-revenue gene therapy with Phase 1/2 data entering pivotal
Base rate: ≈35% probability of at least one BLA approval within 5 years
Prior odds: 0.54

Adjustments from base rate:

• RMAT designation: +15pp (FDA intensive engagement, rolling review)
• 6/6 clean Phase 1/2 (100% responders, 18mo durability): +10pp
• Ultra-rare (<200 US patients, no alternatives): +5pp (FDA flexibility maximal)
• Same organ/approach as LUXTURNA precedent: +5pp
• Manufacturing process change for pivotal (SAFC tech transfer): -5pp
• RDEP pathway untested (zero precedent): -5pp
• Adjusted P(at least one approval from LCA5 + BEST1 + presbyopia) = ≈96% (1 - 0.30 x 0.70 x 0.175, assuming LCA5 70%, BEST1 30%, presbyopia 82.5% PoS, independence)

The portfolio math is favorable: three shots on goal with uncorrelated biology. But individual program PoS matters for sizing.

Alpha vs Beta

Total expected return (12mo):  +40-70% (range reflects doorway state)
  Market beta (0.59 x ≈10%):   +6%
  Sector beta (XBI, ≈0.25):    +4%
  Idiosyncratic alpha:         +30-60%  <- the actual thesis

Variance decomposition:
  Idiosyncratic:  72%
  Market:         10%
  Sector (XBI):   15%
  Style/momentum:  3%

Nearly pure stock-specific risk. The +415% 1Y return is 350pp idiosyncratic (Opus merger, clinical data, sNDA filing) and 65pp sector. Beta 0.59, RSI 46.9 (neutral), short interest 2.9%, RVOL 0.64x. Zero crowding signals. Alpha lives here.

B -- Business Model

Three pillars, three risk profiles, zero product revenue.

Pillar 1: RYZUMVI / Phentolamine (Viatris partnership)

IRD's only current revenue source is Viatris R&D reimbursement -- $14.2M in FY2025 -- under a cost-sharing agreement capped at $50M total. Through December 2025, $37.7M has been consumed, leaving approximately $12.3M before the cap is exhausted (likely late 2026). This is NOT product revenue. RYZUMVI royalties from the approved mydriasis indication were described as "immaterial" in the 10-K.

Viatris pays tiered royalties from low double-digit (≈10-12%) to low 20% (≈20-22%) on US net sales, plus up to $120M in remaining regulatory and commercial milestones. The license covers phentolamine monotherapy AND a phentolamine + low-dose pilocarpine combination for presbyopia. Royalty duration runs through December 31, 2040.

The sNDA for presbyopia was accepted with a PDUFA date of October 17, 2026. P(approval) = 80-85% based on known molecule, supplemental application pathway, two positive Phase 3 trials (VEGA-2 and VEGA-3: 27.2% vs 11.5% placebo on primary endpoint, p<0.0001), and a 1,200+ subject safety database.

The risk is commercial, not regulatory. Vuity (pilocarpine, AbbVie) was effectively abandoned. VIZZ (aceclidine, LENZ) generated $1.6M in its first full quarter, and LENZ stock has fallen 76%. No pharmacological presbyopia drug has achieved meaningful commercial traction. Phentolamine's mechanism is genuinely different -- alpha-adrenergic blockade of the iris dilator muscle rather than muscarinic agonist stimulation of the sphincter, avoiding ciliary muscle engagement entirely. Viatris R&D head Philippe Martin explicitly validated this differentiation on the Q3 2025 earnings call. But "different mechanism" is necessary, not sufficient, for overcoming a sociological barrier: patients prefer $10 reading glasses.

A third indication -- mesopic/low-light visual disturbance after keratorefractive surgery (LYNX-3) -- has an FDA Special Protocol Assessment agreement, Fast Track designation, and topline data expected H1 2026. The addressable market is 210,000-245,000 procedures per year with zero approved treatments.

Pillar 2: OPGx-LCA5 Gene Therapy (AAV8, Phase 1/2/3)

Gene augmentation therapy for Leber Congenital Amaurosis type 5. LCA5 patients retain photoreceptor structure despite near-total loss of function -- the same biological prerequisite that made LUXTURNA work in RPE65-LCA. IRD delivers a working copy of the LCA5 gene via AAV8 subretinal injection, cells produce lebercilin, vision restores.

Phase 1/2 data (6 patients, all improved):

• Adults (n=3, 18-month follow-up): VA improvement averaging 0.35 logMAR (3.5 lines), durable through 18 months. All showed functional improvement on VR-based mobility testing. Retinal sensitivity improved 0.86 log units in treated vs 0.16 in control eyes.
• Pediatric (n=3, 3-month follow-up): Larger gains than adults. One patient +0.7 logMAR at 1 month. All showed >1 log unit cone sensitivity improvement.
• Safety: 0/6 ocular SAEs, 0/6 DLTs across all patients.

FDA agreed to an adaptive Phase 1/2/3 pivotal extension via Type B RMAT meeting (November 2025): as few as 8 patients, single arm, 12-month primary endpoint, each patient serves as own control. Pivotal dosing is anticipated H2 2026, contingent on SAFC Carlsbad completing validated commercial-process manufacturing. Topline data approximately 12 months later, i.e. H2 2027.

Regulatory designations: RMAT + Orphan Drug + Rare Pediatric Disease (PRV eligible). RDEP application was targeted for Q1 2026 but status is unconfirmed as of April 1 -- the first evidence of management timeline slippage.

Addressable population: approximately 170 US patients, 3,260 worldwide. Pricing precedent: LUXTURNA at $850K (2018); gene therapy prices have since inflated to $1.5-3.5M for ultra-rare indications (Hemgenix $3.5M, Elevidys $3.2M). One-time US revenue opportunity: $170-510M plus PRV ($100-350M).

Biologic (BLA pathway): 12-year biologic exclusivity plus 7-year orphan drug exclusivity. No AAV gene therapy biosimilars approved to date. Effective exclusivity estimated at 15-20+ years.

Zero competitors in clinical, preclinical, or academic development for LCA5 gene therapy. HHI = 10,000 (monopoly).

Pillar 3: OPGx-BEST1 Gene Therapy (AAV2, Phase 1/2)

First-in-disease gene therapy for bestrophinopathies. BEST1 patients exhibit slow retinal degeneration with photoreceptors viable for decades, creating a wide therapeutic window. AAV2 (the same serotype as LUXTURNA) delivers functional BEST1 protein to RPE cells.

Preclinical: naturally occurring canine model of Best disease showed lesion regression and dose-dependent ERG improvement. The same investigator (Pennesi) who discovered and characterized this canine model is running the clinical trial. This is the gold standard for preclinical gene therapy validation.

Sentinel patient data (63-year-old female with autosomal recessive bestrophinopathy, BIRD-1 trial): +12 letters BCVA (+2.4 lines), 23% CST reduction, intraretinal fluid resolution at 1 month, no AEs, no DLTs. Two patients treated to date; Cohort 1 (n=3+, multiple phenotypes) three-month data expected mid-2026.

n=1 is n=1. Biological plausibility is established, but no PoS estimate is possible before Cohort 1.

Addressable population: approximately 8,400 US, 22,050 worldwide. This is the larger commercial prize: at gene therapy pricing with 20-40% first-decade penetration, the US TAM is $1.4-5.7B.

Zero competitors in clinical development worldwide. HHI = 10,000 (absolute monopoly).

Structural constraints: Astellas/Iveric holds a right of first refusal on BEST1/RHO assets through approximately December 2028, plus reversion rights that allow Astellas to claw back all BEST1/RHO IP if IRD materially breaches diligence or ceases development. Total milestone burden across two licensors (Iveric/Astellas + Penn/UF) is approximately $186M, plus combined royalties of approximately 4-8% on net sales.

Pipeline: Five additional gene therapy programs totaling approximately 17,200 US patients. MERTK entering clinical trials in Abu Dhabi (2026, non-dilutive funding). RHO is the largest market (8,800 US patients) but requires complex knock-and-replace gene therapy (no approved precedent). Three programs in IND-enabling studies.

Phi -- Financial Trajectory

Pre-revenue clinical biotech with accelerating burn. Margins are irrelevant; the question is runway.

Cash: $45.1M at December 31, 2025. Pro forma approximately $70M including the February 2026 Series B Preferred placement ($25M gross at $3.39/share) and ATM sales ($2.3M). Company guides runway into H1 2028 excluding warrant proceeds or milestones.

Burn: Operating cash flow was -$35.3M in FY2025, up 38% from -$25.6M in FY2024. Gene therapy R&D went from $0.9M to $11.6M (12x). G&A rose 21% to $22.0M. Total recurring operating expenses: $52.8M (excluding the $28M one-time acquired IPR&D charge in FY2024). Expect $38-42M annual OCF burn in FY2026 as LCA5 pivotal and BEST1 expansion proceed.

Revenue cliff: All $14.2M of FY2025 revenue is Viatris R&D reimbursement under a $50M cap, of which $37.7M has been consumed. Approximately $12.3M remains. Revenue drops to near-zero after cap exhaustion (likely late 2026) unless RYZUMVI presbyopia royalties ramp.

Warrant liability: $26.0M on the balance sheet, driving $11.5M of non-cash P&L volatility in FY2025. The 20.2M March 2025 warrants at $0.95 exercise price are callable after BEST1 Cohort 1 data announcement, subject to VWAP and volume conditions (currently met at $4.69). If called and exercised, generates approximately $19M cash and eliminates the warrant liability.

Capital structure constraint: 125M authorized shares, approximately 118.2M issued or reserved. Only approximately 6.8M unreserved. The Series B Preferred ($25M) cannot convert to common without shareholder approval. Annual meeting April 20, 2026: vote to double authorization to 250M. P(passage) >90% based on low threshold (FOR > AGAINST), broker discretionary voting, and aligned shareholder base. If vote fails, the company effectively cannot raise equity, convert the Series B, or call warrants -- catastrophic for capital access.

Balance sheet: Zero traditional debt. $1.1M RDF Agreement (charitable funding from Foundation Fighting Blindness for MERTK program, accounted for as debt at 22.3% effective interest rate). Asset-light: $199K total PP&E. Full valuation allowance on $40M deferred tax assets. $31.5M federal NOL carryforward (no expiration), but Section 382 limitations have not been evaluated for the Opus Acquisition -- latent risk.

Capital allocation: $77.6M raised in 12 months across five rounds at prices from $0.95 to $3.39. Zero buybacks. Zero dividends. APX3330 terminated. 100% deployed to clinical programs. Clean audit (EY, since 2018). Effective internal controls. No going concern language.

K -- Competitive Position

The moat is biological, not commercial:

LCA5: Regulatory barrier (RMAT + Orphan + RPD triple designation, 7+ years post-approval exclusivity), data barrier (6-patient Phase 1/2 with 18-month durability, 5-7 year replication minimum), population barrier (170 US patients is too small for competitor entry), IP (Penn AAV8 platform patents through 2038+). Zero competitors at any stage.

BEST1: First-in-disease globally. The preclinical work that validated BEST1 gene therapy is IRD's own exclusively licensed IP -- no one else has it. The investigator network (Pennesi at OHSU, Penn, University of Florida) is aligned with IRD through exclusive licenses. Zero competitors at any stage.

Presbyopia (RYZUMVI): Differentiated mechanism (alpha-blocker vs cholinergic) in a crowded but commercially unproven market. Four products approved or pending (Vuity -- dead, VIZZ -- failing, YUVEZZI -- launching, RYZUMVI -- PDUFA Oct 2026). Patent estate layered from 2034-2046. Sandoz ANDA Paragraph IV challenge filed January 2025 (mydriasis only, trial January 2027, 30-month automatic stay through August 2027).

M&A comps: Gene therapy ophthalmology companies are acquisition targets (Spark to Roche $4.8B in 2019, MeiraGTx to J&J $1.4B in 2024). IRD at $328M with two monopoly positions fits the pattern. BUT: Astellas ROFR constrains BEST1/RHO-specific deals through December 2028. Astellas itself could be the acquirer. Whole-company acquisition may bypass the ROFR (which applies to asset-level transactions), but this needs legal confirmation.

Manufacturing concentration risk: Both lead gene therapy programs depend on SAFC Carlsbad Inc. (MilliporeSigma) for tech transfer from legacy processes (adherent at academic partners) to commercial-scale suspension processes. BEST1 clinical supply is manufactured separately by Catalent at 200L. LCA5 pivotal dosing is explicitly gated on "validated clinical drug supply manufactured with the intended commercial processes." A quality or capacity issue at SAFC delays both programs simultaneously.

The most relevant manufacturing base rate: Rocket Pharmaceuticals received a Complete Response Letter for KRESLADI (LAD-I gene therapy) specifically for Chemistry, Manufacturing, and Controls issues -- not efficacy. CMC problems are non-trivial in gene therapy.

G -- Governance

Alignment grade: A-.

11.7% insider ownership (13 officers/directors). CEO George Magrath purchased $0.5M at $0.95 in March 2025. Chairman Cam Gallagher purchased $1.0M at $0.95 (March 2025) and $1.0M at $1.12 (August 2025). Both are holding through 5x appreciation with zero selling. Total management net open-market buying (12 months): +$2.48M. The only management sale: COO Schachle sold 3,719 shares ($19.5K) -- tax-related, trivial. FFB (non-profit, 7.7% holder) sold 4M shares at $2.15 in December 2025 -- institutional rebalancing, not thesis-driven.

CEO total compensation: $1.49M, below the $2-4M peer range for $300M biotech CEOs. 60% variable, tied to milestone-driven metrics (clinical 30%, business development 40%, manufacturing 15%, regulatory 15%). This is the correct incentive structure for a pre-revenue biotech -- management is rewarded for pipeline execution, not stock price or revenue.

Board: 7/9 independent. CEO/Chairman split (best practice). Jean Bennett (Luxturna co-inventor) and Richard Rodgers (ex-TESARO CFO, company sold to GSK for $5.1B) provide domain-specific expertise. Declassified board (annual elections), no poison pill. Say-on-pay approval improved from 62.7% to 86% in 2025.

New CFO Robert Gagnon (September 2025): MIT Sloan MBA, former CFO at Verastem and Harvard Bioscience, former Controller at Biogen. Upgrade for capital markets execution. Zero core scientific/operational team turnover.

Change-in-control: 1.5x (salary + target bonus) for CEO with double-trigger and no tax gross-up. Reasonable provisions that encourage management to pursue the best deal rather than resist acquisition.

Institutional holders at 9.99% blockers: Perceptive Advisors (7.17M shares, warrants for 26.8M more), Nantahala Capital (7.12M shares), Balyasny Asset Management (5.11M shares including 2.4M warrant shares). All are healthcare-specialist capital with research depth.

Red flag -- 5% annual evergreen: The equity plan auto-increases by 5% of outstanding shares on January 1 each year through 2030. At 71M shares, this adds approximately 3.6M shares per year. Aggressive for a concentrated shareholder base.

Beta -- Factor Profile

r_IRD = alpha + 0.59*r_SPY + ≈0.25*r_XBI + epsilon

Idiosyncratic variance:  72% (yfinance, near 75% threshold)
Market beta:             0.59 (low)
Short interest:          2.9% (not crowded)
RSI:                     46.9 (neutral)
RVOL:                    0.64x (below average)
1Y return:              +415.4% (vs XBI +65.1%, SPY +18.1%)
Idiosyncratic return:   ≈350pp of the 415% (merger, data, sNDA)

The +415% is catalyst-driven, not momentum-factor exposure. RSI neutral, volume below average, short interest negligible. This is a re-rating event (Opus merger Oct 2024, pipeline derisking, analyst coverage initiation), not a momentum chase.

Hedging XBI exposure pushes idiosyncratic variance above the 75% portfolio construction threshold. Acceptable as-is for a clinical biotech where the entire return profile is event-driven.

Cross-corpus check: zero mentions of Opus Genetics, OPGx, LCA5, BEST1, or bestrophinopathy in any public company earnings transcript (2025-2026 searched). Complete information vacuum. Nobody is watching. Nobody is talking about it. The counterparty on the short side has no primary-source basis for a thesis against the gene therapy programs.

Delta -- Expectations Gap

Standard valuation metrics (P/E, EV/EBITDA) are meaningless for a pre-revenue biotech. The framework is risk-adjusted NPV (rNPV) sum-of-parts.

Market cap (basic):  $328M ($4.69 x 71.1M shares)
Less pro forma cash: -$70M
Enterprise value:    ≈$263M  <- what the market pays for the pipeline

What $263M Implies

Where Primary Sources Diverge

Gap 1: Presbyopia commercial value. Market assigns approximately $30M. Research-based value: $120-145M. Phentolamine MOA is genuinely differentiated (alpha-blocker, no ciliary muscle engagement, confirmed by Viatris R&D head on transcript). P(sNDA approval) = 80-85%. The gap is whether 30-50% commercial success probability (my estimate) vs 10-15% (market-implied) is correct. Two prior drugs failed commercially, but neither had phentolamine's tolerability profile. Resolves: PDUFA October 2026 + commercial launch trajectory through 2027.

Gap 2: BEST1 option value. Market assigns approximately $45M to an absolute global monopoly with 22,000 patients, zero competition, encouraging sentinel data, gold-standard preclinical validation, and wide therapeutic window. Research-based option value: $75-125M. The gap is n=1 vs biological plausibility. Resolves: Cohort 1 data mid-2026 -- the highest-information near-term catalyst.

Gap 3: LCA5 PoS and pricing. Market implies approximately 50% PoS and LUXTURNA-era pricing ($1M). Research supports 65-75% PoS (6/6 clean data, RMAT, ultra-rare FDA flexibility, same biology as LUXTURNA). Gene therapy pricing has inflated: LUXTURNA $850K (2018), Hemgenix $3.5M (2022), Elevidys $3.2M (2023). For approximately 170 US patients, $1.5-2.5M is defensible. Research-based value: $170-200M. Resolves: pivotal topline H2 2027 (slow).

Gap 4 (negative): Manufacturing execution risk. Not priced by market, consensus, or any analyst. SAFC Carlsbad tech transfer is gating for LCA5 pivotal dosing. Process change from adherent to suspension is a different product biologically, requiring comparability studies. Both lead programs depend on the same CDMO. RCKT CRL for CMC (not efficacy) is the relevant base rate. Research-based discount: -$20-30M. Resolves: unknown (tech transfer status is not public).

Net delta (basic shares):
  Positive: +$90M (presbyopia) + $55M (BEST1) + $35M (LCA5) + $25M (pipeline/M&A) = +$205M
  Negative: -$25M (manufacturing) - $5M (RDEP uncertainty) = -$30M
  Net: +$175M = +$2.46/share

  Research-implied fair value: ≈$7.15/share (basic) vs $9.90 consensus vs $4.69 market

Below consensus because: I price manufacturing execution risk that no one models, I'm more skeptical on presbyopia commercial viability (q=0.65), and I discount BEST1 more heavily given n=1.

Above market because: LCA5 data quality justifies higher PoS, gene therapy pricing has inflated since 2018, BEST1 monopoly has real option value even pre-Cohort 1, phentolamine MOA is genuinely different (counterparty-validated on transcript).

Management Guidance vs Reality

Management guided RDEP application for Q1 2026. Q1 ended March 31; no confirmation. This is the first evidence of timeline slippage. Management guides LCA5 pivotal dosing "H2 2026" -- but the 10-K qualifies this as contingent on SAFC tech transfer: "Following availability of validated clinical drug supply manufactured with the intended commercial processes." Consensus models this as calendared. It is conditional.

Steelman Bear Case

The strongest argument against the thesis is not about the science. It's about the math of the addressable market and the structural constraints on monetization.

LCA5 has approximately 170 US patients. Even at $2M per patient with 70% penetration and 70% PoS, the one-time US revenue is approximately $167M. Add a PRV ($125M) and international ($30M). Total economic value: approximately $320M -- but spread over 5-7 years of patient identification and treatment. After $186M in BEST1 milestone obligations, the company needs sustained capital access (which depends on the April 20 vote), manufacturing execution (single-CDMO dependency), and years of patient enrollment in ultra-rare populations where genetic testing infrastructure is still developing.

Meanwhile, the burn rate is $35-40M per year and accelerating. The revenue cliff from Viatris reimbursement ($12.3M remaining) hits in late 2026. The company has raised $78M in 12 months, tripling share count. Even if every program succeeds, the economics are gene-therapy-scale, not blockbuster-scale. LUXTURNA's cumulative revenue from 2018-2023 was approximately $250M -- underwhelming relative to pre-approval projections.

BEST1 is larger (8,400 US patients) but further from approval (n=1, Phase 1/2), constrained by Astellas ROFR through 2028, and burdened with $186M in milestones across two licensors. Presbyopia is commercially unproven across two prior entrants. And the entire edifice rests on a single CDMO (SAFC Carlsbad) completing tech transfers for both lead programs.

The counterargument: the monopoly positions are real, the science is sound, governance is strong, and the stock is priced for the bear case. But "priced for the bear case" at $328M still requires meaningful value creation from at least one program to justify the current price plus the dilution needed to fund operations through approval. The bear case is not a company-ending event (P(portfolio failure) is only approximately 4%). The bear case is that the value creation is real but smaller, slower, and more diluted than the bull thesis implies -- and that $4.69 already prices enough of the upside that the risk-adjusted return is merely adequate, not exceptional.

This is the honest assessment: the thesis lives or dies on whether BEST1 Cohort 1 confirms multi-patient efficacy (repricing the monopoly option value) and whether SAFC manufacturing executes on time (preserving the LCA5 timeline). Without BEST1, the portfolio is a small ultra-orphan gene therapy plus a dubious presbyopia royalty stream -- interesting but not compelling at $328M. With BEST1, it's a dual-monopoly platform with two uncorrelated shots on goal and an M&A precedent that commands $1B+.

Kill Criteria

Thesis dies if:
- April 20 shareholder vote fails -> exit immediately (capital access blocked)
- BEST1 Cohort 1 shows no improvement in 2+ patients or SAEs -> cut to monitoring only
- SAFC manufacturing CRL/delay publicly disclosed -> exit (both programs impacted)
- Cash drops below $30M without funded path to next catalyst -> exit (survival risk)

Thesis weakened if:
- RDEP denied or materially delayed beyond Q2 2026 -> reduce PoS to 55-60%
- RYZUMVI PDUFA CRL -> accelerates revenue cliff, reduce fair value by $1/share
- Insider selling >$500K by CEO or Chairman -> reassess alignment

Thesis strengthened if:
- BEST1 Cohort 1 shows multi-patient improvement (mid-2026) -> increase BEST1 option value to $150M+
- ARVO pediatric 6-month data confirms durability -> increase LCA5 PoS to 70-75%
- SAFC tech transfer confirmed complete -> remove manufacturing discount
- Warrant call executed -> $19M cash + eliminates $26M liability

Options Timing

The options chain is thin (total OI approximately 9,000 contracts across 4 expirations) but informative:

$5 ceiling (material through May 15): 1,975 combined call OI at the $5 strike. Dealer delta hedging creates resistance above $5. Gamma peaks at ATM. After May 15 OPEX (68% of all OI expires), the ceiling lifts.

No floors anywhere. Total put OI across all expirations: approximately 120 contracts. If the thesis breaks, the stock drops through air. Size accordingly.

Positioning is unanimously bullish. P/C ratio 0.00 to 0.42 across all expirations. 5,348 deep ITM $2 calls are leveraged long positions. The crowd is long and unhedged. Moves will be violent in either direction.

IV term structure is inverted (79.7% near-term to 119.1% at 232 days). Market expects vol to increase as catalysts approach. August IV at 107% (99th percentile of 52-week range) correctly prices the BEST1 binary. No edge in options; the vol is fairly priced.

Implied distribution (May 15, 43 days): 13% below $2, 38% at $2-5, 38% at $5-8, 11% above $8. For August (141 days, BEST1 window): flatter -- 13% below $2, 27% at $2-5, 29% at $5-8, 31% above $8. Classic binary catalyst signature.

Entry timing: Post-vote (April 21-30) while May $5 ceiling compresses price. The $0.40 discount from entering before the ceiling lifts justifies the 19-day alpha decay (SR_wait = 1.08, above the 0.5 threshold). After May 15, the ceiling lifts and ARVO data compounds the thesis.

Key Risks

1. Manufacturing execution (SAFC Carlsbad). Both lead programs depend on the same CDMO completing tech transfers. LCA5 pivotal dosing is explicitly gated on "validated clinical drug supply." Process change (adherent to suspension) creates biological comparability risk. RCKT CRL for CMC is the relevant precedent. Status is not public.

2. Authorized share vote (April 20). P(passage) >90%, but failure is catastrophic: cannot convert $25M Series B, cannot raise equity, cannot call warrants. At $70M cash with $40M annual burn, failure constrains all options to debt or structured products at unfavorable terms.

3. Presbyopia market viability. Two prior entrants failed commercially. IRD bears the base rate unless phentolamine demonstrably overcomes the sociological barrier (patients preferring $10 glasses). Commercial evidence won't exist until 2027 at earliest.

4. Timeline slippage. RDEP application guided for Q1 2026, unconfirmed. LCA5 dosing "H2 2026" is conditional, not calendared. Management timelines appear aspirational.

5. Astellas ROFR and reversion. ROFR constrains M&A on BEST1/RHO through December 2028. Reversion rights create execution risk: if IRD ceases development (e.g., runs out of capital), Astellas claws back all BEST1/RHO IP.

6. Small-n clinical risk. 6 patients for LCA5, 1 for BEST1. Open-label, no randomized control. Practice effects could inflate subjective endpoints. The pivotal trial (8 patients) is also small, though FDA agreed to this design.

What to Watch

LR Signal

LR = 1.4 (mild bullish divergence from market pricing).

Market prices the bear case across all three pillars. Research confirms the monopoly positions are real, the clinical data is clean, and governance is strong. But: the timeline is longer than consensus models suggest (LCA5 topline H2 2027, not 2026), manufacturing execution risk is unpriced, and presbyopia commercial viability is genuinely uncertain.

The strongest bullish signal is the information vacuum: zero cross-corpus transcript mentions, uninformed counterparty, and informed biotech capital (Perceptive, Balyasny, Nantahala) on the long side at blocker limits. The strongest bearish signal is the manufacturing dependency on a single CDMO with process change risk, which nobody -- market, consensus, or any analyst -- is modeling.

Net: mild bullish. Not strong bullish because: (a) my fair value ($7.15 basic) is below consensus ($9.90), meaning the market is already partially right; (b) the catalysts that close the gap are months to quarters away; (c) the doorway state has a genuine 40% bear path. LR reflects divergence from market, not conviction.

Evidence